ANAVEON
Anaveon are developing IL-2 complexes which selectively promote effector T cell functions. Our compounds act as effective immune adjuvants with a broad therapeutic window and marked preclinical efficacy against cancer either as monotherapy or in combination with other therapies.
ANAVEON
Social Links:
Industry:
Therapeutics
Founded:
2017-01-01
Address:
Bottmingen, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.anaveon.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
145 M CHF
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro Apple Mobile Web Clips Icon Google Analytics Mobile Non Scaleable Content Google Universal Analytics Apple Mobile Web App Capable Apple Mobile Web App Status Bar Style
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Current Advisors List
Current Employees Featured
Founder
Investors List
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Anaveon
Syncona Partners LLP
Syncona Partners LLP investment in Series B - Anaveon
Pontifax
Pontifax investment in Series B - Anaveon
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Anaveon
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series B - Anaveon
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Anaveon
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Anaveon
Syncona Partners LLP
Syncona Partners LLP investment in Series A - Anaveon
Official Site Inspections
http://www.anaveon.com Semrush global rank: 5.9 M Semrush visits lastest month: 1.18 K
- Host name: sl359.web.hostpoint.ch
- IP address: 217.26.54.171
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Anaveon"
About - ANAVEON
Developing Therapies to Benefit Patients. Anaveon’s mission is to harness the power of the immune system for life-changing treatments. The Company was founded in 2017 by scientists …See details»
Anaveon - Crunchbase Company Profile & Funding
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.See details»
Investors - ANAVEON
In 2022, Anaveon secured a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by …See details»
ANAVEON AG - LinkedIn
Anaveon is a global clinical stage biopharmaceutical company that specialises in developing novel treatments for diseases with high unmet needs.See details»
Anaveon AG Company Profile | Basel, BASEL-STADT, Switzerland ...
Find company research, competitor information, contact details & financial data for Anaveon AG of Basel, BASEL-STADT. Get the latest business insights from Dun & Bradstreet.See details»
Anaveon - Org Chart, Teams, Culture & Jobs | The Org
View Anaveon's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Anaveon AG - VentureRadar
"Anaveon develops novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology and develops a selective IL-2 Receptor Agonist, a type of …See details»
Success story Anaveon - BaseLaunch
Anaveon develops biologics that modulate cytokine functionality for immune dysfunction diseases. Founded in 2017 based on IP from the University of Zurich and Novartis, Anaveon’s initial funding came from BaseLaunch. In 2018, …See details»
Anaveon AG - Tech Park Basel
May 29, 2024 Anaveon AG Anaveon is a clinical stage company committed to transforming immunological insights into life-saving therapies. With a vision to use our expertise in cutting …See details»
Anaveon AG - Swiss Biotech
Anaveon is a clinical phase biopharmaceutical company that specialises in the development of treatments for diseases with immune system dysfunction.See details»
Anaveon | Clinical companies | Portfolio | Syncona
Anaveon was fouded in 2017 and is a pre-clinical phase biopharmaceutical company that specialises in the development of treatments for diseases with immune system dysfunction.See details»
Anaveon - Funding, Financials, Valuation & Investors
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.See details»
Anaveon's Leadership Team Team - Team members and org chart
The leadership team at Anaveon has a long history of experience in the software engineering field.See details»
Anaveon AG - VentureRadar
Anaveon develops novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology and develops a selective IL-2 Receptor Agonist, a type of …See details»
Syncona, Novartis back IL-2 immuno-oncology startup Anaveon
Feb 26, 2019 The antibody in preclinical development at Anaveon is designed to unleash the positive effects of IL-2 on cytotoxic effector cells while preventing the unwanted stimulation of …See details»
Science - ANAVEON
Immunology and Protein Engineering. Anaveon’s roots lie in the field of immuno-oncology, where it has built a robust foundation of expertise in harnessing the immune system’s potential to …See details»
Anaveon - Forbion
Anaveon is a clinical stage, biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to …See details»
Enable Profound Impact | CRO Selection | Life Science Consulting
They designed a thorough selection process with sequential steps that allowed ample input from Anaveon. Their data-driven methodology collected qualitative and quantitative insights, …See details»
News - ANAVEON
Anaveon appoints Dieter Weinand as Chair of its Board of Directors Basel, July 30, 2024 – Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of …See details»